Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
286. |
ECCT/25/05/03 | Hibiscus 2 - Site 253 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Site 253 - International Cancer Institute (Uasin Gishu county) |
View |
287. |
ECCT/25/05/06 | Hibiscus 2 - Site 254 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
288. |
ECCT/25/05/02 | Hibiscus 2 - Site 251 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county) |
View |
289. |
ECCT/25/04/04 | LIMIT A Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Principal Investigator(s) 1. Anthony KIBUKA Gikonyo Site(s) in Kenya The Karen Hospital |
View |
290. |
ECCT/22/03/04 | VIBRI COVID-19-001/2021 A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda). |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute, |
View |